Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Change in Accured Expenses (2022 - 2025)

Neuraxis' Change in Accured Expenses history spans 4 years, with the latest figure at $138170.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 157.85% year-over-year to $138170.0; the TTM value through Sep 2025 reached $726989.0, down 18.29%, while the annual FY2024 figure was $949693.0, 422.86% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $138170.0 at Neuraxis, down from $251028.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $592114.0 in Q2 2024 and bottomed at -$755499.0 in Q3 2023.
  • The 4-year median for Change in Accured Expenses is $153489.0 (2023), against an average of $92881.5.
  • The largest YoY upside for Change in Accured Expenses was 645.19% in 2023 against a maximum downside of 7233.52% in 2023.
  • A 4-year view of Change in Accured Expenses shows it stood at $16241.0 in 2022, then soared by 645.19% to $121027.0 in 2023, then soared by 49.56% to $181007.0 in 2024, then decreased by 23.67% to $138170.0 in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Change in Accured Expenses are $138170.0 (Q3 2025), $251028.0 (Q2 2025), and $156784.0 (Q1 2025).